Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France
To estimate the statistical distribution of the incubation period of Creutzfeldt-Jakob disease (CJD) in human growth hormone (hGH) recipients in France. Published papers suggest that the median incubation period of hGH-related CJD is approximately 15 years, but there are as yet no statistical data t...
Gespeichert in:
| Veröffentlicht in: | Neurology 1999-10, Vol.53 (6), p.1197-1201 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1201 |
|---|---|
| container_issue | 6 |
| container_start_page | 1197 |
| container_title | Neurology |
| container_volume | 53 |
| creator | HUILLARD D'AIGNAUX, J COSTAGLIOLA, D ALPEROVITCH, A MACCARIO, J BILLETTE DE VILLEMEUR, T BRANDEL, J. P DESLYS, J. P HAUW, J. J CHAUSSAIN, J. L AGID, Y DORMONT, D |
| description | To estimate the statistical distribution of the incubation period of Creutzfeldt-Jakob disease (CJD) in human growth hormone (hGH) recipients in France.
Published papers suggest that the median incubation period of hGH-related CJD is approximately 15 years, but there are as yet no statistical data that support this assertion.
Of the 1,361 hGH recipients who were included in this study, 55 had developed CJD at the time of the study. Individual data on hGH treatment history were available. Different mathematical models were used to estimate the statistical distribution of the incubation period. One main feature of the models was to take into account the occurrence of future CJD cases.
Models showed that the mean incubation period was 9 to 10 years, and the 95th percentile of the distribution was 15 to 16 years. Data and models indicated that the incubation period was significantly shorter in homozygotes at codon 129 of the prion protein gene than in heterozygotes.
The short mean incubation period of CJD in French hGH recipients may be due to high infectivity in hormone lots. Estimates of the 95th percentile indicate that the number of hGH-related CJD cases may continue to increase in the coming years. |
| doi_str_mv | 10.1212/wnl.53.6.1197 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70818524</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70818524</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-b1aa521a55524952eb027bf018091b566aefbe5aa7a95cfd3f807ce5a87af4503</originalsourceid><addsrcrecordid>eNpN0EFr3DAQBWARGpJtkmOvRYeSmzeSbFnysSxJmrIkl5QGchBjedRVa0tbySYkv75edqE5Dcx8PJhHyCfOllxwcfUS-qUsl_WS80YdkQWXoi7qUjx9IAvGhC5KrfQp-Zjzb8bmo2pOyClnUgitxII83wU7tTD6GOgWk48djY6uEk7jm8O-G4vv8Ce2tPMZISP1gW6mAQL9leLLuKGbmIYYkCa0fusxjHlHbhIEi-fk2EGf8eIwz8iPm-vH1bdi_XB7t_q6Lmypq7FoOYAUHKSUomqkwJYJ1TrGNWt4K-sa0LUoARQ00rqudJopOy-0AldJVp6Ry33uNsW_E-bRDD5b7HsIGKdsFNNcz9kzLPbQpphzQme2yQ-QXg1nZtem-Xm_NrI0tdm1OfvPh-CpHbB7p_f1zeDLAUC20Lvd2z7_d42q6oqV_wCHZX3o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70818524</pqid></control><display><type>article</type><title>Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>Journals@Ovid Complete</source><creator>HUILLARD D'AIGNAUX, J ; COSTAGLIOLA, D ; ALPEROVITCH, A ; MACCARIO, J ; BILLETTE DE VILLEMEUR, T ; BRANDEL, J. P ; DESLYS, J. P ; HAUW, J. J ; CHAUSSAIN, J. L ; AGID, Y ; DORMONT, D</creator><creatorcontrib>HUILLARD D'AIGNAUX, J ; COSTAGLIOLA, D ; ALPEROVITCH, A ; MACCARIO, J ; BILLETTE DE VILLEMEUR, T ; BRANDEL, J. P ; DESLYS, J. P ; HAUW, J. J ; CHAUSSAIN, J. L ; AGID, Y ; DORMONT, D</creatorcontrib><description>To estimate the statistical distribution of the incubation period of Creutzfeldt-Jakob disease (CJD) in human growth hormone (hGH) recipients in France.
Published papers suggest that the median incubation period of hGH-related CJD is approximately 15 years, but there are as yet no statistical data that support this assertion.
Of the 1,361 hGH recipients who were included in this study, 55 had developed CJD at the time of the study. Individual data on hGH treatment history were available. Different mathematical models were used to estimate the statistical distribution of the incubation period. One main feature of the models was to take into account the occurrence of future CJD cases.
Models showed that the mean incubation period was 9 to 10 years, and the 95th percentile of the distribution was 15 to 16 years. Data and models indicated that the incubation period was significantly shorter in homozygotes at codon 129 of the prion protein gene than in heterozygotes.
The short mean incubation period of CJD in French hGH recipients may be due to high infectivity in hormone lots. Estimates of the 95th percentile indicate that the number of hGH-related CJD cases may continue to increase in the coming years.</description><identifier>ISSN: 0028-3878</identifier><identifier>EISSN: 1526-632X</identifier><identifier>DOI: 10.1212/wnl.53.6.1197</identifier><identifier>PMID: 10522872</identifier><identifier>CODEN: NEURAI</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Biological and medical sciences ; Creutzfeldt-Jakob Syndrome - epidemiology ; Drug toxicity and drugs side effects treatment ; Female ; France - epidemiology ; Human Growth Hormone ; Humans ; Incidence ; Male ; Medical sciences ; Models, Neurological ; Pharmacology. Drug treatments ; Time Factors ; Toxicity: nervous system and muscle</subject><ispartof>Neurology, 1999-10, Vol.53 (6), p.1197-1201</ispartof><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-b1aa521a55524952eb027bf018091b566aefbe5aa7a95cfd3f807ce5a87af4503</citedby><cites>FETCH-LOGICAL-c384t-b1aa521a55524952eb027bf018091b566aefbe5aa7a95cfd3f807ce5a87af4503</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1974640$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10522872$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HUILLARD D'AIGNAUX, J</creatorcontrib><creatorcontrib>COSTAGLIOLA, D</creatorcontrib><creatorcontrib>ALPEROVITCH, A</creatorcontrib><creatorcontrib>MACCARIO, J</creatorcontrib><creatorcontrib>BILLETTE DE VILLEMEUR, T</creatorcontrib><creatorcontrib>BRANDEL, J. P</creatorcontrib><creatorcontrib>DESLYS, J. P</creatorcontrib><creatorcontrib>HAUW, J. J</creatorcontrib><creatorcontrib>CHAUSSAIN, J. L</creatorcontrib><creatorcontrib>AGID, Y</creatorcontrib><creatorcontrib>DORMONT, D</creatorcontrib><title>Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France</title><title>Neurology</title><addtitle>Neurology</addtitle><description>To estimate the statistical distribution of the incubation period of Creutzfeldt-Jakob disease (CJD) in human growth hormone (hGH) recipients in France.
Published papers suggest that the median incubation period of hGH-related CJD is approximately 15 years, but there are as yet no statistical data that support this assertion.
Of the 1,361 hGH recipients who were included in this study, 55 had developed CJD at the time of the study. Individual data on hGH treatment history were available. Different mathematical models were used to estimate the statistical distribution of the incubation period. One main feature of the models was to take into account the occurrence of future CJD cases.
Models showed that the mean incubation period was 9 to 10 years, and the 95th percentile of the distribution was 15 to 16 years. Data and models indicated that the incubation period was significantly shorter in homozygotes at codon 129 of the prion protein gene than in heterozygotes.
The short mean incubation period of CJD in French hGH recipients may be due to high infectivity in hormone lots. Estimates of the 95th percentile indicate that the number of hGH-related CJD cases may continue to increase in the coming years.</description><subject>Biological and medical sciences</subject><subject>Creutzfeldt-Jakob Syndrome - epidemiology</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Female</subject><subject>France - epidemiology</subject><subject>Human Growth Hormone</subject><subject>Humans</subject><subject>Incidence</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Models, Neurological</subject><subject>Pharmacology. Drug treatments</subject><subject>Time Factors</subject><subject>Toxicity: nervous system and muscle</subject><issn>0028-3878</issn><issn>1526-632X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpN0EFr3DAQBWARGpJtkmOvRYeSmzeSbFnysSxJmrIkl5QGchBjedRVa0tbySYkv75edqE5Dcx8PJhHyCfOllxwcfUS-qUsl_WS80YdkQWXoi7qUjx9IAvGhC5KrfQp-Zjzb8bmo2pOyClnUgitxII83wU7tTD6GOgWk48djY6uEk7jm8O-G4vv8Ce2tPMZISP1gW6mAQL9leLLuKGbmIYYkCa0fusxjHlHbhIEi-fk2EGf8eIwz8iPm-vH1bdi_XB7t_q6Lmypq7FoOYAUHKSUomqkwJYJ1TrGNWt4K-sa0LUoARQ00rqudJopOy-0AldJVp6Ry33uNsW_E-bRDD5b7HsIGKdsFNNcz9kzLPbQpphzQme2yQ-QXg1nZtem-Xm_NrI0tdm1OfvPh-CpHbB7p_f1zeDLAUC20Lvd2z7_d42q6oqV_wCHZX3o</recordid><startdate>19991012</startdate><enddate>19991012</enddate><creator>HUILLARD D'AIGNAUX, J</creator><creator>COSTAGLIOLA, D</creator><creator>ALPEROVITCH, A</creator><creator>MACCARIO, J</creator><creator>BILLETTE DE VILLEMEUR, T</creator><creator>BRANDEL, J. P</creator><creator>DESLYS, J. P</creator><creator>HAUW, J. J</creator><creator>CHAUSSAIN, J. L</creator><creator>AGID, Y</creator><creator>DORMONT, D</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19991012</creationdate><title>Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France</title><author>HUILLARD D'AIGNAUX, J ; COSTAGLIOLA, D ; ALPEROVITCH, A ; MACCARIO, J ; BILLETTE DE VILLEMEUR, T ; BRANDEL, J. P ; DESLYS, J. P ; HAUW, J. J ; CHAUSSAIN, J. L ; AGID, Y ; DORMONT, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-b1aa521a55524952eb027bf018091b566aefbe5aa7a95cfd3f807ce5a87af4503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Biological and medical sciences</topic><topic>Creutzfeldt-Jakob Syndrome - epidemiology</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Female</topic><topic>France - epidemiology</topic><topic>Human Growth Hormone</topic><topic>Humans</topic><topic>Incidence</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Models, Neurological</topic><topic>Pharmacology. Drug treatments</topic><topic>Time Factors</topic><topic>Toxicity: nervous system and muscle</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HUILLARD D'AIGNAUX, J</creatorcontrib><creatorcontrib>COSTAGLIOLA, D</creatorcontrib><creatorcontrib>ALPEROVITCH, A</creatorcontrib><creatorcontrib>MACCARIO, J</creatorcontrib><creatorcontrib>BILLETTE DE VILLEMEUR, T</creatorcontrib><creatorcontrib>BRANDEL, J. P</creatorcontrib><creatorcontrib>DESLYS, J. P</creatorcontrib><creatorcontrib>HAUW, J. J</creatorcontrib><creatorcontrib>CHAUSSAIN, J. L</creatorcontrib><creatorcontrib>AGID, Y</creatorcontrib><creatorcontrib>DORMONT, D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HUILLARD D'AIGNAUX, J</au><au>COSTAGLIOLA, D</au><au>ALPEROVITCH, A</au><au>MACCARIO, J</au><au>BILLETTE DE VILLEMEUR, T</au><au>BRANDEL, J. P</au><au>DESLYS, J. P</au><au>HAUW, J. J</au><au>CHAUSSAIN, J. L</au><au>AGID, Y</au><au>DORMONT, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France</atitle><jtitle>Neurology</jtitle><addtitle>Neurology</addtitle><date>1999-10-12</date><risdate>1999</risdate><volume>53</volume><issue>6</issue><spage>1197</spage><epage>1201</epage><pages>1197-1201</pages><issn>0028-3878</issn><eissn>1526-632X</eissn><coden>NEURAI</coden><abstract>To estimate the statistical distribution of the incubation period of Creutzfeldt-Jakob disease (CJD) in human growth hormone (hGH) recipients in France.
Published papers suggest that the median incubation period of hGH-related CJD is approximately 15 years, but there are as yet no statistical data that support this assertion.
Of the 1,361 hGH recipients who were included in this study, 55 had developed CJD at the time of the study. Individual data on hGH treatment history were available. Different mathematical models were used to estimate the statistical distribution of the incubation period. One main feature of the models was to take into account the occurrence of future CJD cases.
Models showed that the mean incubation period was 9 to 10 years, and the 95th percentile of the distribution was 15 to 16 years. Data and models indicated that the incubation period was significantly shorter in homozygotes at codon 129 of the prion protein gene than in heterozygotes.
The short mean incubation period of CJD in French hGH recipients may be due to high infectivity in hormone lots. Estimates of the 95th percentile indicate that the number of hGH-related CJD cases may continue to increase in the coming years.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>10522872</pmid><doi>10.1212/wnl.53.6.1197</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-3878 |
| ispartof | Neurology, 1999-10, Vol.53 (6), p.1197-1201 |
| issn | 0028-3878 1526-632X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70818524 |
| source | MEDLINE; Alma/SFX Local Collection; Journals@Ovid Complete |
| subjects | Biological and medical sciences Creutzfeldt-Jakob Syndrome - epidemiology Drug toxicity and drugs side effects treatment Female France - epidemiology Human Growth Hormone Humans Incidence Male Medical sciences Models, Neurological Pharmacology. Drug treatments Time Factors Toxicity: nervous system and muscle |
| title | Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T01%3A04%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Incubation%20period%20of%20Creutzfeldt-Jakob%20disease%20in%20human%20growth%20hormone%20recipients%20in%20France&rft.jtitle=Neurology&rft.au=HUILLARD%20D'AIGNAUX,%20J&rft.date=1999-10-12&rft.volume=53&rft.issue=6&rft.spage=1197&rft.epage=1201&rft.pages=1197-1201&rft.issn=0028-3878&rft.eissn=1526-632X&rft.coden=NEURAI&rft_id=info:doi/10.1212/wnl.53.6.1197&rft_dat=%3Cproquest_cross%3E70818524%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70818524&rft_id=info:pmid/10522872&rfr_iscdi=true |